Yabing Nan

5PUBLICATIONS
19CO-AUTHORS
Molecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 02, 2026
Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP.

|Feb 24, 2026
Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer.

Yabing Nan, Kunyu Wang, Menghan Hu

|Nov 24, 2025
IRG1/itaconate/NRF2/GSH axis in tumor-associated macrophages drives therapy resistance and immune evasion in BRCA1-deficient breast cancer.

Yabing Nan, Sophie O'keefe, Xiadi He

|May 03, 2024
OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition.

Yabing Nan, Xiaowei Wu, Qingyu Luo

|Jun 22, 2022
DLGAP1-AS2-Mediated Phosphatidic Acid Synthesis Activates YAP Signaling and Confers Chemoresistance in Squamous Cell Carcinoma.

Yabing Nan, Qingyu Luo, Xiaowei Wu

Pageof 1

Frequent Collaborators

5 joint publications

Qingyu Luo

4 joint publications

Xiaowei Wu

3 joint publications

Zhihua Liu

1 joint publications

Aiping Zhou